Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming

Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer
Staging Project: proposals for the revision of the TNM stage groupings
in the forthcoming (seventh) edition of the TNM Classification of
malignant tumours. J Thorac Oncol 2007 Aug;2(8):706–714.
2. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small
cell lung cancer: a decade of progress. Chest 2002 Sep;122(3):1037–1057.
3. Harpole DH Jr, Herndon JE II, Wolfe WG, et al. A prognostic model
of recurrence and death in stage I non-small cell lung cancer utilizing
presentation, histopathology, and oncoprotein expression. Cancer Res
1995 Jan 1;55(1):51–56.
4. Nemunaitis J, Klemow S, Tong A, et al. Prognostic value of K-ras mutations,
ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma
of the lung. Am J Clin Oncol 1998 Apr;21(2):155–160.
5. Nishio M, Koshikawa T, Yatabe Y, et al. Prognostic significance of
cyclin D1 and retinoblastoma expression in combination with p53
abnormalities in primary, resected non-small cell lung cancers. Clin
Cancer Res 1997 Jul;3(7):1051–1058.
6. Breuer RH, Postmus PE, Smit EF. Molecular pathology of non-smallcell
lung cancer. Respiration 2005 May-Jun;72(3):313–330.
7. Kaye FJ. Molecular biology of lung cancer. Lung Cancer 2001 Dec;34
(Suppl 2):S35–S41.
8. Ahrendt SA, Decker PA, Alawi EA, et al. Cigarette smoking is strongly
associated with mutation of the K-ras gene in patients with primary
adenocarcinoma of the lung. Cancer 2001 Sep 15;92(6):1525–1530.
9. Westra WH, Baas IO, Hruban RH, et al. K-ras oncogene activation
in atypical alveolar hyperplasias of the human lung. Cancer Res 1996
May 1;56(9):2224–2228.
10. Fischer JR, Lahm H. Validation of molecular and immunological
factors with predictive importance in lung cancer. Lung Cancer 2004
Aug;45(Suppl 2):S151–S161.
11. Huncharek M, Muscat J, Geschwind JF. K-ras oncogene mutation as a
prognostic marker in non-small cell lung cancer: a combined analysis
of 881 cases. Carcinogenesis 1999 Aug;20(8):1507–1510.
12. Vielh P, Spano JP, Grenier J, et al. Molecular prognostic factors in
resectable non-small cell lung cancer. Crit Rev Oncol Hematol 2005
Mar;53(3):193–197.
13. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive
importance of p53 and RAS for adjuvant chemotherapy in
non small-cell lung cancer. J Clin Oncol 2007 Nov 20;25(33):
5240–5247.
14. Ahrendt SA, Chow JT, Yang SC, et al. Alcohol consumption and cigarette
smoking increase the frequency of p53 mutations in non-small
cell lung cancer. Cancer Res 2000 Jun 15;60(12):3155–3159.
15. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature
2000 Nov 16;408(6810):307–310.
16. Ahrendt SA, Hu Y, Buta M, et al. p53 mutations and survival in stage I
non-small-cell lung cancer: results of a prospective study. J Natl Cancer
Inst 2003 Jul 2;95(13):961–970.
17. Fukuyama Y, Mitsudomi T, Sugio K, et al. K-ras and p53 mutations
are an independent unfavourable prognostic indicator in
patients with non-small-cell lung cancer. Br J Cancer 1997;75(8):
1125–1130.
18. Hashimoto T, Tokuchi Y, Hayashi M, et al. p53 null mutations undetected
by immunohistochemical staining predict a poor outcome
with early-stage non-small cell lung carcinomas. Cancer Res 1999 Nov
1;59(21):5572–5577.
19. Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53
mutations and 3p deletions in primary resected non-small cell lung
cancer. Cancer Res 1993 Jan 1;53(1):1–4.
20. Huang CL, Taki T, Adachi M, et al. Mutations of p53 and K-ras genes
as prognostic factors for non-small cell lung cancer. Int J Oncol 1998
Mar;12(3):553–563.
21. Laudanski J, Niklinska W, Burzykowski T, et al. Prognostic significance
of p53 and bcl-2 abnormalities in operable nonsmall cell lung cancer.
Eur Respir J 2001 Apr;17(4):660–666.
22. Mitsudomi T, Oyama T, Kusano T, et al. Mutations of the p53 gene
as a predictor of poor prognosis in patients with non-small-cell lung
cancer. J Natl Cancer Inst 1993 Dec 15;85(24):2018–2023.
23. Skaug V, Ryberg D, Kure EH, et al. p53 mutations in defined structural
and functional domains are related to poor clinical outcome in
non-small cell lung cancer patients. Clin Cancer Res 2000 Mar;6(3):
1031–1037.
24. Tomizawa Y, Kohno T, Fujita T, et al. Correlation between the status of
the p53 gene and survival in patients with stage I non-small cell lung
carcinoma. Oncogene 1999 Jan 28;18(4):1007–1014.
25. Vega FJ, Iniesta P, Caldés T, et al. p53 exon 5 mutations as a prognostic
indicator of shortened survival in non-small-cell lung cancer. Br
J Cancer 1997;76(1):44–51.
26. Dalquen P, Sauter G, Torhorst J, et al. Nuclear p53 overexpression is
an independent prognostic parameter in node-negative non-small cell
lung carcinoma. J Pathol 1996 Jan;178(1):53–58.
27. D’Amico TA, Massey M, Herndon JE II, et al. A biologic risk model
for stage I lung cancer: immunohistochemical analysis of 408 patients
with the use of ten molecular markers. J Thorac Cardiovasc Surg 1999
Apr;117(4):736–743.
28. Kwiatkowski DJ, Harpole DH Jr, Godleski J, et al. Molecular pathologic
substaging in 244 stage I non-small-cell lung cancer patients:
clinical implications. J Clin Oncol 1998 Jul;16(7):2468–2477.
29. Lee YC, Chang YL, Luh SP, et al. Significance of P53 and Rb protein
expression in surgically treated non-small cell lung cancers. Ann Thorac
Surg 1999 Aug;68(2):343–347; discussion 348.
30. Moldvay J, Scheid P, Wild P, et al. Predictive survival markers in patients
with surgically resected non-small cell lung carcinoma. Clin
Cancer Res 2000 Mar;6(3):1125–1134.
31. Nishio M, Koshikawa T, Kuroishi T, et al. Prognostic significance of
abnormal p53 accumulation in primary, resected non-small-cell lung
cancers. J Clin Oncol 1996 Feb;14(2):497–502.
32. Pappot H, Francis D, Brünner N, et al. p53 protein in non-small
cell lung cancer as quantitated by enzyme-linked immunosorbent
assay: relation to prognosis. Clin Cancer Res 1996 Jan;2(1):
155–160.
33. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical
markers in stage I lung cancer: relevance to prognosis. J Clin Oncol
1997 Aug;15(8):2858–2865.
34. Carbognani P, Tincani G, Crafa P, et al. Biological markers in nonsmall
cell lung cancer. Retrospective study of 10 year follow-up after
surgery. J Cardiovasc Surg (Torino) 2002 Aug;43(4):545–548.
35. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic
factor for survival in lung cancer: a systematic review of the literature
with a meta-analysis. Eur Respir J 2001 Oct;18(4):705–719.
36. Akin H, Yilmazbayhan D, Kilicaslan Z, et al. Clinical significance of
P16INK4A and retinoblastoma proteins in non-small-cell lung carcinoma.
Lung Cancer 2002 Dec;38(3):253–260.
37. Haga Y, Hiroshima K, Iyoda A, et al. Ki-67 expression and prognosis
for smokers with resected stage I non-small cell lung cancer. Ann
Thorac Surg 2003 Jun;75(6):1727–1732; discussion 1732–1733.
38. Jin M, Inoue S, Umemura T, et al. Cyclin D1, p16 and retinoblastoma
gene product expression as a predictor for prognosis in non-small
cell lung cancer at stages I and II. Lung Cancer 2001 Nov;34(2):
207–218.
39. Burke L, Flieder DB, Guinee DG, et al. Prognostic implications of
molecular and immunohistochemical profiles of the Rb and p53 cell
cycle regulatory pathways in primary non-small cell lung carcinoma.
Clin Cancer Res 2005 Jan 1;11(1):232–241.
40. Mohamed S, Yasufuku K, Hiroshima K, et al. Prognostic implications
of cell cycle-related proteins in primary resectable pathologic N2 nonsmall
cell lung cancer. Cancer 2007 Jun 15;109(12):2506–2514.
41. Groeger AM, Caputi M, Esposito V, et al. Independent prognostic
role of p16 expression in lung cancer. J Thorac Cardiovasc Surg 1999
Sep;118(3):529–535.
42. Huang CI, Taki T, Higashiyama M, et al. p16 protein expression is associated
with a poor prognosis in squamous cell carcinoma of the lung.
Br J Cancer 2000 Jan;82(2):374–380.
43. Kawabuchi B, Moriyama S, Hironaka M, et al. p16 inactivation in
small-sized lung adenocarcinoma: its association with poor prognosis.
Int J Cancer 1999 Feb 19;84(1):49–53.
44. Kratzke RA, Greatens TM, Rubins JB, et al. Rb and p16INK4a expression
in resected non-small cell lung tumors. Cancer Res 1996 Aug
1;56(15):3415–3420.
45. Keum JS, Kong G, Yang SC, et al. Cyclin D1 overexpression is an
indicator of poor prognosis in resectable non-small cell lung cancer. Br
J Cancer 1999 Sep;81(1):127–132.
46. Gugger M, Kappeler A, Vonlanthen S, et al. Alterations of cell cycle
regulators are less frequent in advanced non-small cell lung cancer
than in resectable tumours. Lung Cancer 2001 Aug-Sep;33(2–3):
229–239.
47. Fukuse T, Hirata T, Naiki H, et al. Prognostic significance of cyclin E
overexpression in resected non-small cell lung cancer. Cancer Res 2000
Jan 15;60(2):242–244.
48. Mishina T, Dosaka-Akita H, Hommura F, et al. Cyclin E expression,
a potential prognostic marker for non-small cell lung cancers. Clin
Cancer Res 2000 Jan;6(1):11–16.
49. Soria JC, Rodriguez M, Liu DD, et al. Aberrant promoter methylation
of multiple genes in bronchial brush samples from former cigarette
smokers. Cancer Res 2002 Jan 15;62(2):351–355.
50. Esposito V, Baldi A, De Luca A, et al. Prognostic role of the cyclindependent
kinase inhibitor p27 in non-small cell lung cancer. Cancer
Res 1997 Aug 15;57(16):3381–3385.
51. Komiya T, Hosono Y, Hirashima T, et al. p21 expression as a predictor
for favorable prognosis in squamous cell carcinoma of the lung. Clin
Cancer Res 1997 Oct;3(10):1831–1835.
52. Shoji T, Tanaka F, Takata T, et al. Clinical significance of p21 expression in
non-small-cell lung cancer. J Clin Oncol 2002 Sep 15;20(18):3865–3871.
53. Hayashi H, Ogawa N, Ishiwa N, et al. High cyclin E and low p27/Kip1
expressions are potentially poor prognostic factors in lung adenocarcinoma
patients. Lung Cancer 2001 Oct;34(1):59–65.
54. Hommura F, Dosaka-Akita H, Mishina T, et al. Prognostic significance
of p27KIP1 protein and ki-67 growth fraction in non-small cell lung
cancers. Clin Cancer Res 2000 Oct;6(10):4073–4081.
55. Tsukamoto S, Sugio K, Sakada T, et al. Reduced expression of cell-cycle
regulator p27(Kip1) correlates with a shortened survival in non-small
cell lung cancer. Lung Cancer 2001 Oct;34(1):83–90.
56. Scagliotti GV, Selvaggi G, Novello S, et al. The biology of epidermal
growth factor receptor in lung cancer. Clin Cancer Res 2004 Jun 15;10
(12 Pt 2):S4227–S4232.
57. Johnson BE, Jänne PA. Epidermal growth factor receptor mutations
in patients with non-small cell lung cancer. Cancer Res 2005 Sep
1;65(17):7525–7529.
58. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three
Akts. Genes Dev 1999 Nov 15;13(22):2905–2927.
59. Jeon YK, Sung SW, Chung JH, et al. Clinicopathologic features and
prognostic implications of epidermal growth factor receptor (EGFR)
gene copy number and protein expression in non-small cell lung cancer.
Lung Cancer 2006 Dec 28;54(3):387–398.
60. Murray S, Timotheadou E, Linardou H, et al. Mutations of the epidermal
growth factor receptor tyrosine kinase domain and associations
with clinicopathological features in non-small cell lung cancer patients.
Lung Cancer 2006 May;52(2):225–233.
61. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer:
correlation with clinical response to gefitinib therapy. Science 2004 Jun
4;304(5676):1497–1500.
62. Pham D, Kris MG, Riely GJ, et al. Use of cigarette-smoking history to
estimate the likelihood of mutations in epidermal growth factor receptor
gene exons 19 and 21 in lung adenocarcinomas. J Clin Oncol 2006
Apr 10;24(11):1700–1704.
63. Sugio K, Uramoto H, Ono K, et al. Mutations within the tyrosine kinase
domain of EGFR gene specifically occur in lung adenocarcinoma
patients with a low exposure of tobacco smoking. Br J Cancer 2006
Mar 27;94(6):896–903.
64. Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial
of chemotherapy-naive patients or 70 years of age treated with
erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007
Mar 1;25(7):760–766.
65. Reck M, Crinò L. Advances in anti-VEGF and anti-EGFR therapy for
advanced non-small cell lung cancer. Lung Cancer 2009 Jan;63(1):1–9.
66. Suzuki M, Shigematsu H, Hiroshima K, et al. Epidermal growth factor
receptor expression status in lung cancer correlates with its mutation.
Hum Pathol 2005 Oct;36(10):1127–1134.
67. Meert AP, Martin B, Delmotte P, et al. The role of EGF-R expression
on patient survival in lung cancer: a systematic review with metaanalysis.
Eur Respir J 2002 Oct;20(4):975–981.
68. Bunn PA Jr, Helfrich B, Soriano AF, et al. Expression of Her-2/neu in
human lung cancer cell lines by immunohistochemistry and fluorescence
in situ hybridization and its relationship to in vitro cytotoxicity
by trastuzumab and chemotherapeutic agents. Clin Cancer Res 2001
Oct;7(10):3239–3250.
69. Lee JW, Soung YH, Kim SY, et al. ERBB2 kinase domain mutation
in the lung squamous cell carcinoma. Cancer Lett 2006 Jun
8;237(1):89–94.
70. Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic
ERBB2 kinase mutations in tumours. Nature 2004 Sep 30;431(7008):
525–526.
71. Hsieh CC, Chow KC, Fahn HJ, et al. Prognostic significance of HER-
2/neu overexpression in stage I adenocarcinoma of lung. Ann Thorac
Surg 1998 Oct;66(4):1159–1163; discussion 1163–1164.
72. Saad RS, Liu Y, Han H, et al. Prognostic significance of HER2/neu,
p53, and vascular endothelial growth factor expression in early stage
conventional adenocarcinoma and bronchioloalveolar carcinoma of the
lung. Mod Pathol 2004 Oct;17(10):1235–1242.
73. Sekido Y, Fong KM, Minna JD. Molecular genetics of lung cancer.
Annu Rev Med 2003;54:73–87.
74. Selvaggi G, Scagliotti GV, Torri V, et al. HER-2/neu overexpression in
patients with radically resected nonsmall cell lung carcinoma. Impact
on long-term survival. Cancer 2002 May 15;94(10):2669–2674.
75. Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and
overexpression of vascular endothelial growth factor are associated with
unfavourable prognosis in operated small cell lung carcinoma. Br J
Cancer 2002 Feb 12;86(4):558–563.
76. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth
factor expression in stage I non-small cell lung cancer correlates with
neoangiogenesis and a poor prognosis. Ann Surg Oncol 2001 Jan-Feb;
8(1):72–79.
77. Singhal S, Vachani A, Antin-Ozerkis D, et al. Prognostic implications
of cell cycle, apoptosis, and angiogenesis biomarkers in nonsmall
cell lung cancer: a review. Clin Cancer Res 2005 Jun 1;11(11):
3974–3986.
78. Azim HA Jr, Ganti AK. Targeted therapy in advanced non-small cell
lung cancer (NSCLC): where do we stand? Cancer Treat Rev 2006
Dec;32(8):630–636.
79. Aita M, Fasola G, Defferrari C, et al. Targeting the VEGF pathway:
Antiangiogenic strategies in the treatment of non-small cell lung cancer.
Crit Rev Oncol Hematol 2008 Dec;68(3):183–196.
80. Arenberg DA, Polverini PJ, Kunkel SL, et al. The role of CXC chemokines
in the regulation of angiogenesis in non-small cell lung cancer.
J Leukoc Biol 1997 Nov;62(5):554–562.
81. Yuan A, Yang PC, Yu CJ, et al. Interleukin-8 messenger ribonucleic
acid expression correlates with tumor progression, tumor angiogenesis,
patient survival, and timing of relapse in non-small-cell lung cancer.
Am J Respir Crit Care Med 2000 Nov;162(5):1957–1963.
82. Takanami I, Imamura T, Yamamoto Y, et al. Usefulness of plateletderived
growth factor as a prognostic factor in pulmonary adenocarcinoma.
J Surg Oncol 1995 Jan;58(1):40–43.
83. Nissen LJ, Cao R, Hedlund EM, et al. Angiogenic factors FGF2 and
PDGF-BB synergistically promote murine tumor neovascularization
and metastasis. J Clin Invest 2007 Oct;117(10):2766–2777.
84. Brown PD, Bloxidge RE, Stuart NS, et al. Association between expression
of activated 72-kilodalton gelatinase and tumor spread in non-smallcell
lung carcinoma. J Natl Cancer Inst 1993 Apr 7;85(7):574–578.
85. Passlick B, Sienel W, Seen-Hibler R, et al. Overexpression of matrix
metalloproteinase 2 predicts unfavorable outcome in early-stage nonsmall
cell lung cancer. Clin Cancer Res 2000 Oct;6(10):3944–3948.
86. Liu D, Nakano J, Ishikawa S, et al. Overexpression of matrix metalloproteinase-
7 (MMP-7) correlates with tumor proliferation, and a poor
prognosis in non-small cell lung cancer. Lung Cancer 2007 Dec;58(3):
384–391.
87. Cox G, Jones JL, O’Byrne KJ. Matrix metalloproteinase 9 and the epidermal
growth factor signal pathway in operable non-small cell lung
cancer. Clin Cancer Res 2000 Jun;6(6):2349–2355.
88. Shou Y, Hirano T, Gong Y, et al. Influence of angiogenetic factors and
matrix metalloproteinases upon tumour progression in non-small-cell
lung cancer. Br J Cancer 2001 Nov 30;85(11):1706–1712.
89. Sienel W, Hellers J, Morresi-Hauf A, et al. Prognostic impact of matrix
metalloproteinase-9 in operable non-small cell lung cancer. Int J Cancer
2003 Feb 20;103(5):647–651.
90. Sienel W, Polzer B, Elshawi K, et al. Cellular localization of
EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma
independent from MMP-2 and MMP-9. Mod Pathol 2008
Sep;21(19):1130–1138.
91. Katakura H, Takenaka K, Nakagawa M, et al. Maspin gene expression
is a significant prognostic factor in resected non-small cell lung
cancer (NSCLC). Maspin in NSCLC. Lung Cancer 2006 Mar;51(3):
323–328.
92. Takanami I, Abiko T, Koizumi S. Expression of maspin in non-smallcell
lung cancer: correlation with clinical features. Clin Lung Cancer
2008 Nov;9(6):361–366.
93. Zheng HC, Saito H, Masuda S, et al. Cytoplasmic and nuclear
maspin expression in lung carcinomas: an immunohistochemical study
using tissue microarrays. Appl Immunohistochem Mol Morphol 2008
Oct;16(5):459–465.
94. Nakagawa M, Katakura H, Adachi M, et al. Maspin expression and its
clinical significance in non-small cell lung cancer. Ann Surg Oncol 2006
Nov;13(11):1517–1523.
95. Lonardo F, Li X, Siddiq F, et al. Maspin nuclear localization is linked to
favorable morphological features in pulmonary adenocarcinoma. Lung
Cancer 2006 Jan;51(1):31–39.
96. Meyerson M, Carbone D. Genomic and proteomic profiling of lung
cancers: lung cancer classification in the age of targeted therapy. J Clin
Oncol 2005 May 10;23(14):3219–3226.
97. Dobbin KK, Beer DG, Meyerson M, et al. Interlaboratory comparability
study of cancer gene expression analysis using oligonucleotide
microarrays. Clin Cancer Res 2005 Jan 15;11(2 Pt 1):565–572.
98. Granville CA, Dennis PA. An overview of lung cancer genomics and
proteomics. Am J Respir Cell Mol Biol 2005 Mar;32(3):169–176.
99. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of
human lung carcinomas by mRNA expression profiling reveals distinct
adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001 Nov 20;
98(24):13790–13795.
100. Hayes DN, Monti S, Parmigiani G, et al. Gene expression profiling
reveals reproducible human lung adenocarcinoma subtypes in multiple
independent patient cohorts. J Clin Oncol 2006 Nov 1;24(31):
5079–5090.
101. Petty RD, Nicolson MC, Kerr KM, et al. Gene expression profiling
in non-small cell lung cancer: from molecular mechanisms to clinical
application. Clin Cancer Res 2004 May 15;10(10):3237–3248.
102. Beer DG, Kardia SL, Huang CC, et al. Gene-expression profiles predict
survival of patients with lung adenocarcinoma. Nat Med 2002
Aug;8(8):816–824.
103. Raponi M, Zhang Y, Yu J, et al. Gene expression signatures for predicting
prognosis of squamous cell and adenocarcinomas of the lung.
Cancer Res 2006 Aug 1;66(15):7466–7472.
104. Iwao K, Watanabe T, Fujiwara Y, et al. Isolation of a novel human
lung-specific gene, LUNX, a potential molecular marker for detection
of micrometastasis in non-small-cell lung cancer. Int J Cancer 2001 Feb
15;91(4):433–437.
105. Travis WD, Brambilla E, Müller-Hermelink HK, et al., eds. World
Health Organisation Classification of Tumors . Pathology and Genetics
of Tumours of the Lung, Pleura, Thymus and Heart. 4th Ed. Geneva:
WHO, 2004.
106. Yousem SA, Beasley MB. Bronchioloalveolar carcinoma: a review
of current concepts and evolving issues. Arch Pathol Lab Med 2007
Jul;131(7):1027–1032.
107. Balsara BR, Testa JR. Chromosomal imbalances in human lung cancer.
Oncogene 2002 Oct 7;21(45):6877–6883.
108. Luk C, Tsao MS, Bayani J, et al. Molecular cytogenetic analysis of
non-small cell lung carcinoma by spectral karyotyping and comparative
genomic hybridization. Cancer Genet Cytogenet 2001 Mar;125(2):
87–99.
109. Sato S, Nakamura Y, Tsuchiya E. Difference of allelotype between
squamous cell carcinoma and adenocarcinoma of the lung. Cancer Res
1994 Nov 1;54(21):5652–5655.
110. Shiseki M, Kohno T, Nishikawa R, et al. Frequent allelic losses on chromosomes
2q, 18q, and 22q in advanced non-small cell lung carcinoma.
Cancer Res 1994 Nov 1;54(21):5643–5648.
111. Fong KM, Sekido Y, Minna JD. Molecular pathogenesis of lung cancer.
J Thorac Cardiovasc Surg 1999 Dec;118(6):1136–1152.
112. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin
Oncol 1998 Mar;16(3):1207–1217.
113. Petersen S, Heckert C, Rudolf J, et al. Gene expression profiling of
advanced lung cancer. Int J Cancer 2000 May 15;86(4):512–517.
114. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression
in adenocarcinoma of the lung. Proc Natl Acad Sci U S A 2001
Nov 20;98(24):13784–13789.
114a. Nacht M, Dracheva T, Gao Y, et al. Molecular characteristics of non-small
cell lung cancer. Proc Natl Acad Sci U S A 2001;98(26):15203–15208.
115. McDoniels-Silvers AL, Nimri CF, Stoner GD, et al. Differential gene
expression in human lung adenocarcinomas and squamous cell carcinomas.
Clin Cancer Res 2002 Apr;8(4):1127–1138.
116. Nakamura H, Saji H, Ogata A, et al. cDNA microarray analysis of
gene expression in pathologic Stage IA nonsmall cell lung carcinomas.
Cancer 2003 Jun 1;97(11):2798–2805.
117. Wikman H, Kettunen E, Seppänen JK, et al. Identification of differentially
expressed genes in pulmonary adenocarcinoma by using cDNA
array. Oncogene 2002 Aug 22;21(37):5804–5813.
118. Kang SH, Choi HH, Kim SG, et al. Transcriptional inactivation of the
tissue inhibitor of metalloproteinase-3 gene by dna hypermethylation
of the 5 -CpG island in human gastric cancer cell lines. Int J Cancer
2000 Jun 1;86(5):632–635.
119. Karameris A, Panagou P, Tsilalis T, et al. Association of expression of
metalloproteinases and their inhibitors with the metastatic potential of
squamous-cell lung carcinomas. A molecular and immunohistochemical
study. Am J Respir Crit Care Med 1997 Dec;156(6):1930–1936.
120. Nawrocki B, Polette M, Marchand V, et al. Expression of matrix metalloproteinases
and their inhibitors in human bronchopulmonary carcinomas:
quantificative and morphological analyses. Int J Cancer 1997
Aug 7;72(4):556–564.
121. Heighway J, Knapp T, Boyce L, et al. Expression profiling of primary nonsmall
cell lung cancer for target identification. Oncogene 2002 Oct 31;
21(50):7749–7763.
122. Miura K, Bowman ED, Simon R, et al. Laser capture microdissection
and microarray expression analysis of lung adenocarcinoma reveals tobacco
smoking- and prognosis-related molecular profiles. Cancer Res
2002 Jun 1;62(11):3244–3250.
123. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion
region on human chromosome 3p21.3: identification and evaluation of
the resident candidate tumor suppressor genes. The International Lung
Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium.
Cancer Res 2000 Nov 1;60(21):6116–6133.
124. Wigle DA, Jurisica I, Radulovich N, et al. Molecular profiling of nonsmall
cell lung cancer and correlation with disease-free survival. Cancer
Res 2002 Jun 1;62(11):3005–3008.
125. Kikuchi T, Daigo Y, Katagiri T, et al. Expression profiles of non-small
cell lung cancers on cDNA microarrays: identification of genes for prediction
of lymph-node metastasis and sensitivity to anti-cancer drugs.
Oncogene 2003 Apr 10;22(14):2192–2205.
126. Inamura K, Togashi Y, Okui M, et al. HOXB2 as a novel prognostic indicator
for stage I lung adenocarcinomas [erratum in: J Thorac Oncol 2008;
3(1):100. Ishikawa, Yuichi (added)]. J Thorac Oncol 2007;2(9):802–807.
127. Hoang CD, D’Cunha J, Tawfic SH, et al. Expression profiling of nonsmall
cell lung carcinoma identifies metastatic genotypes based on lymph
node tumor burden. J Thorac Cardiovasc Surg 2004;127(5):1332–1341;
discussion 1342.
128. Xi L, Coello MC, Litle VR, et al. A combination of molecular markers
accurately detects lymph node metastasis in non-small cell lung cancer
patients. Clin Cancer Res 2006;12(8):2484–2491.
129. Fukata M, Kaibuchi K. Rho-family GTPases in cadherin-mediated
cell-cell adhesion. Nat Rev Mol Cell Biol 2001 Dec;2(12):887–897.
130. Ichigotani Y, Yokozaki S, Fukuda Y, et al. Forced expression of NESH
suppresses motility and metastatic dissemination of malignant cells.
Cancer Res 2002 Apr 15;62(8):2215–2219.
131. Meyaard L, van der Vuurst de Vries AR, de Ruiter T, et al. The epithelial
cellular adhesion molecule (Ep-CAM) is a ligand for the leukocyteassociated
immunoglobulin-like receptor (LAIR). J Exp Med 2001 Jul 2;
194(1):107–112.
132. Wieland I, Arden KC, Michels D, et al. Isolation of DICE1: a gene
frequently affected by LOH and downregulated in lung carcinomas.
Oncogene 1999 Aug 12;18(32):4530–4537.
133. Xi L, Lyons-Weiler J, Coello MC, et al. Prediction of lymph node metastasis
by analysis of gene expression profiles in primary lung adenocarcinomas.
Clin Cancer Res 2005 Jun 1;11(11):4128–4135.
134. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine
prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006
Aug 10;355(6):570–580.
135. Chen HY, Yu SL, Chen CH, et al. A five-gene signature and clinical outcome
in non-small-cell lung cancer. N Engl J Med 2007 Jan 4;356(1):11–20.
136. Furukawa T, Sunamura M, Motoi F, et al. Potential tumor suppressive
pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol
2003 Jun;162(6):1807–1815.
137. Kumar A, Commane M, Flickinger TW, et al. Defective TNF-alphainduced
apoptosis in STAT1-null cells due to low constitutive levels of
caspases. Science 1997 Nov 28;278(5343):1630–1632.
138. Mahabeleshwar GH, Das R, Kundu GC. Tyrosine kinase, p56lckinduced
cell motility, and urokinase-type plasminogen activator
secretion involve activation of epidermal growth factor receptor/
extracellular signal regulated kinase pathways. J Biol Chem 2004 Mar 12;
279(11):9733–9742.
139. Mahabeleshwar GH, Kundu GC. Tyrosine kinase p56lck regulates
cell motility and nuclear factor kappaB-mediated secretion of urokinase
type plasminogen activator through tyrosine phosphorylation
of IkappaBalpha following hypoxia/reoxygenation. J Biol Chem 2003
Dec 26;278(52):52598–52612.
140. Muller-Tidow C, Diederichs S, Bulk E, et al. Identification of metastasisassociated
receptor tyrosine kinases in non-small cell lung cancer. Cancer
Res 2005 Mar 1;65(5):1778–1782.
141. Yu H, Jove R. The STATs of cancer—new molecular targets come of
age. Nat Rev Cancer 2004 Feb;4(2):97–105.
142. Zamoyska R, Basson A, Filby A, et al. The influence of the src-family
kinases, Lck and Fyn, on T cell differentiation, survival and activation.
Immunol Rev 2003 Feb;191:107–118.
143. Herbst RS, Lippman SM. Molecular signatures of lung cancer—
toward personalized therapy. N Engl J Med 2007 Jan 4;356(1):76–78.
144. Potti A, Nevins JR. Utilization of genomic signatures to direct use of
primary chemotherapy. Curr Opin Genet Dev 2008 Feb;18(1):62–67.
145. Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific
gene expression signatures predict lung cancer survival. J Clin Oncol
2008 Feb 20;26(6):877–883.
146. Skrzypski M, Jassem E, Taron M, et al. Three-gene expression signature
predicts survival in early-stage squamous cell carcinoma of the lung.
Clin Cancer Res 2008 Aug 1;14(15):4794–4799.
147. Raz DJ, Ray MR, Kim JY, et al. A multigene assay is prognostic of
survival in patients with early-stage lung adenocarcinoma. Clin Cancer
Res 2008 Sep 1;14(17):5565–5570.
148. Director’s Challenge Consortium for the Molecular Classification of
Lung Adenocarcinoma, Shedden K, Taylor JM, et al. Gene expressionbased
survival prediction in lung adenocarcinoma: a multi-site, blinded
validation study. Nat Med 2008 Aug;14(8):822–827.
149. Belinsky SA. Gene-promoter hypermethylation as a biomarker in lung
cancer. Nat Rev Cancer 2004 Sep;4(9):707–717.
150. Kim DH, Nelson HH, Wiencke JK, et al. Promoter methylation of
DAP-kinase: association with advanced stage in non-small cell lung
cancer. Oncogene 2001 Mar 29;20(14):1765–1770.
151. Lu C, Soria JC, Tang X, et al. Prognostic factors in resected stage I nonsmall-
cell lung cancer: a multivariate analysis of six molecular markers.
J Clin Oncol 2004 Nov 15;22(22):4575–4583.
152. Toyooka KO, Toyooka S, Virmani AK, et al. Loss of expression and
aberrant methylation of the CDH13 (H-cadherin) gene in breast and
lung carcinomas. Cancer Res 2001 Jun 1;61(11):4556–4560.
153. Zöchbauer-Müller S, Fong KM, Virmani AK, et al. Aberrant promoter
methylation of multiple genes in non-small cell lung cancers. Cancer
Res 2001 Jan 1;61(1):249–255.
154. Liu D, Huang C, Kameyama K, et al. E-cadherin expression associated
with differentiation and prognosis in patients with non-small cell
lung cancer. Ann Thorac Surg 2001 Mar;71(3):949–954; discussion
954–955.
155. Bearzatto A, Conte D, Frattini M, et al. p16(INK4A) Hypermethylation
detected by fluorescent methylation-specific PCR in plasmas from nonsmall
cell lung cancer. Clin Cancer Res 2002 Dec;8(12):3782–3787.
156. Digel W, Lübbert M. DNA methylation disturbances as novel therapeutic
target in lung cancer: preclinical and clinical results. Crit Rev
Oncol Hematol 2005 Jul;55(1):1–11.
157. Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histologyspecific
methylation of CpG islands by exposure to tobacco smoke in
non-small cell lung cancer. Cancer Res 2001 Apr 15;61(8):3419–3424.
158. Toyooka S, Suzuki M, Maruyama R, et al. The relationship between
aberrant methylation and survival in non-small-cell lung cancers. Br
J Cancer 2004 Aug 16;91(4):771–774.
159. Burbee DG, Forgacs E, Zöchbauer-Müller S, et al. Epigenetic inactivation
of RASSF1A in lung and breast cancers and malignant phenotype
suppression. J Natl Cancer Inst 2001 May 2;93(9):691–699.
160. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS
association domain family protein from the lung tumour suppressor
locus 3p21.3. Nat Genet 2000 Jul;25(3):315–319.
161. Harden SV, Tokumaru Y, Westra WH, et al. Gene promoter hypermethylation
in tumors and lymph nodes of stage I lung cancer patients.
Clin Cancer Res 2003 Apr;9(4):1370–1375.
162. Gu J, Berman D, Lu C, et al. Aberrant promoter methylation profile
and association with survival in patients with non-small cell lung cancer.
Clin Cancer Res 2006 Dec 15;12(24):7329–7338.
163. Brock MV, Hooker CM, Ota-Machida E, et al. DNA methylation
markers and early recurrence in stage I lung cancer. N Engl J Med 2008
Mar 13;358(11):1118–1128.
164. Anderson L, Seilhamer J. A comparison of selected mRNA and
protein abundances in human liver. Electrophoresis 1997 Mar-Apr;
18(3–4):533–537.
165. Chen G, Gharib TG, Huang CC, et al. Discordant protein and
mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002
Apr;1(4):304–313.
166. Oh JM, Brichory F, Puravs E, et al. A database of protein expression in
lung cancer. Proteomics 2001 Oct;1(10):1303–1319.
167. Li C, Xiao Z, Chen Z, et al. Proteome analysis of human lung squamous
carcinoma. Proteomics 2006 Jan;6(2):547–558.
168. Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour
subsets in non-small-cell lung cancer. Lancet 2003 Aug 9;362(9382):
433–439.
169. Gharib TG, Chen G, Wang H, et al. Proteomic analysis of cytokeratin
isoforms uncovers association with survival in lung adenocarcinoma.
Neoplasia 2002 Sep-Oct;4(5):440–448.
170. Chen G, Gharib TG, Wang H, et al. Protein profiles associated with survival
in lung adenocarcinoma. Proc Natl Acad Sci U S A 2003 Nov 11;
100(23):13537–13542.
171. Yanagisawa K, Tomida S, Shimada Y, et al. A 25-signal proteomic signature
and outcome for patients with resected non-small-cell lung cancer.
J Natl Cancer Inst 2007 Jun 6;99(11):858–867.
172. Lau NC, Lim LP, Weinstein EG, et al. An abundant class of tiny RNAs
with probable regulatory roles in Caenorhabditis elegans. Science 2001
Oct 26;294(5543):858–862.
173. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the
let-7 microRNA family. Cell 2005 Mar 11;120(5):635–647.
174. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 2004 Jan 23;116(2):281–297.
175. Gregory RI, Shiekhattar R. MicroRNA biogenesis and cancer. Cancer
Res 2005 May 1;65(9):3509–3512.
176. Yi R, Qin Y, Macara IG, et al. Exportin-5 mediates the nuclear export
of pre-microRNAs and short hairpin RNAs. Genes Dev 2003 Dec 15;
17(24):3011–3016.
177. Lee Y, Jeon K, Lee JT, et al. MicroRNA maturation: stepwise processing
and subcellular localization. Embo J 2002 Sep 2;21(17):4663–4670.
178. Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates
microRNA processing. Nature 2003 Sep 25;425(6956):415–419.
179. Eder M, Scherr M. MicroRNA and lung cancer. N Engl J Med 2005
Jun 9;352(23):2446–2448.
180. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat
Rev Cancer 2006 Nov;6(11):857–866.
181. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular
profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006
Mar;9(3):189–198.
182. Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of mature
microRNA-21 and microRNA-205 overexpression in non-small
cell lung cancer by quantitative real-time RT-PCR. Clin Chem 2008
Oct;54(10):1696–1704.
183. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival
and relapse in lung cancer. Cancer Cell 2008 Jan;13(1):48–57.
184. Takamizawa J, Konishi H, Yanagisawa K, et al. Reduced expression
of the let-7 microRNAs in human lung cancers in association with
shortened postoperative survival. Cancer Res 2004 Jun 1;64(11):
3753–3756.
185. Weiss GJ, Bemis LT, Nakajima E, et al. EGFR regulation by microRNA
in lung cancer: correlation with clinical response and survival
to gefitinib and EGFR expression in cell lines. Ann Oncol 2008 Jun;
19(6):1053–1059.
186. Anguiano A, Potti A. Genomic signatures individualize therapeutic decisions
in non-small-cell lung cancer. Expert Rev Mol Diagn 2007 Nov;
7(6):837–844.